Blood
Articles in this Issue
Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.
Abstract Introduction: Graft Failure (GF) is a rare but devastating outcome of HCT. Primary GF (PGF), defined as a failure of neutrophil rec...
Impact of MGUS on comorbidities and outcomes in patients with multiple myeloma: A propensity-matched analysis
Abstract Background: Multiple myeloma (MM) is a clonal plasma cell neoplasm projected to affect approximately 36,000 people and result in 12...
primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma
Abstract Chimeric antigen receptor (CAR) T-cell therapy is curative for many patients with non-Hodgkin lymphoma (NHL). However, toxicity rem...
Immune cell tumor engagers (SITE) via morpholino-guided self-assembly for precision immunotherapy of multiple myeloma
Abstract Introduction: Bispecific T cell engagers have shown significant clinical efficacy and are currently FDA approved for the treatment...
Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients
Abstract Introduction: DDX41 (DEAD-box helicase 41) mutations (mt) represent the most prevalent germline predisposition syndrome (GPS) in ad...
Proteolysis-targeting chimera (PROTAC) targeting bruton tyrosine kinase (BTK) degradation for cancer therapy in mantle cell lymphoma
Abstract Background Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma sub-type characterized by Bruton tyrosine kinase (BTK)-signaling wh...
R-cmop and pola-R-CMP regimens as first-line treatment for diffuse large B-cell lymphoma with cardiac comorbidity: A prospective, single-arm, multicenter study
Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma (NHL), accounts for approximat...
Title first‑in‑human Phase 1 dose‑finding study (VIPER 101) of dual‑population autologous CD5‑deleted anti-CD5 CAR‑T (Senza5 CART5) cells in Relapsed/Refractory T‑cell lymphomas
Abstract Background. T-cell lymphomas carry a very poor prognosis and lack effective treatments. Despite the transformative success of chime...
Effectiveness of comprehensive geriatric assessment (CGA) in older patients with diffuse large B-cell lymphoma (DLBCL) and the impact of frailty in treatment tolerability and survival in a prospective, multicenter study.
Abstract Introduction: In high-income countries, half of new hematological malignancy diagnoses are made in patients aged 75 years or older,...
Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial
Abstract Introduction: Chemoimmunotherapy is a standard initial treatment for patients (pts) with high-tumor burden foll...
Real world test characteristics of mass spectrometry monoclonal protein monitoring in multiple myeloma
Abstract Introduction Matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS, mass fix) represents a sen...
MRD-seq: A sensitive next generation sequencing-based approach for measurable residual disease detection in acute myeloid leukaemia
Abstract Acute myeloid leukaemia (AML) is an aggressive and genetically heterogeneous malignancy of the haematopoietic system, characterised...
Glucose transporter 5 enhances CAR-T cell metabolic function and serial killing
Abstract Physiologic serum fructose levels range from 20-150. In the context of AML, fructose accumulates in the bone marrow, reaching conce...
Vedolizumab for treating steroid-refractory lower gastrointestinal acute graft-versus-host disease: a single-center real-world study
Abstract Introduction: Steroid-refractory lower gastrointestinal acute graft-versus-host disease (SR-LGI-aGVHD) remains a life-threatening c...
Real-world treatment patterns for Hemophilia A since the launch of emicizumab in the US
Abstract Introduction: Emicizumab is a recombinant, humanized, bispecific, monoclonal antibody that has become the standard of care in hemop...
Trans-auricular vagal nerve stimulation as an innovative approach to pain treatment in sickle cell disease patients hospitalized with acute pain.
Abstract Sickle cell disease (SCD) pain can lead to frequent hospitalization and reliance on opioid medications. Trans-auricular vagal nerve...
Classical hematology education in pediatric hematology/oncology fellowship: A national needs assessment
Abstract Introduction: Standardized content outlines exist for the education of Pediatric Hematology/Oncology (PHO) fellows during the three...
Impact of germline and somatic TP53 mutations on allogeneic HSCT outcomes in hematologic malignancies
Abstract Introduction TP53 mutations (TP53mut) are strongly associated with chemoresistance, early relapse, and inferior survival in hematol...
Longitudinal biomarker dynamics for accurate risk prediction in 464 patients with asymptomatic IgM gammopathy: A spanish multicenter study
Abstract INTRODUCTION Asymptomatic IgM gammopathies (IgM monoclonal gammopathy of undetermined significance [MGUS] and a...
Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study
Abstract Background: Covalent Bruton tyrosine kinase inhibitors (cBTKi) have been an important advancement for the treatment of WM, but thei...
Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts
Abstract Background Previous studies in aggressive B-cell lymphoma demonstrate that patients with shorter diagnosis-to-treatment intervals (...
Thrombosis and outcomes in hematologic neoplasia: Experience from a specialized cancer center in a developing country
Abstract Introduction: Cancer is a hypercoagulable state due to host, tumor, or treatment-related factors, with a 9-fold increased risk of ve...
Cytokine release syndrome prophylaxis strategy with dipyrone in patients receiving bispecific Antibodies—Elranatamab, teclistamab, talquetamab and Epcoritamab—at a private hospital in southern Brazil: Preliminary Results
Abstract Introduction Bispecific antibodies have improved progression-free survival and overall survival in relapsed/refractory haematologic...
Temporal trends and demographic disparities in myelodysplastic syndrome-associated mortality in Acute Myeloid Leukemia patients in the United States: A population-based analysis (1999–2023)
Abstract Background: Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis and a ris...
Cardiotoxicity profile of novel bispecific T-cell engager therapies
Abstract Background Bispecific T-cell engagers (BTEs) have transformed the treatment of hematologic malignancies. The most recently approved...